U.S. markets open in 7 hours 26 minutes
  • S&P Futures

    +32.25 (+0.72%)
  • Dow Futures

    +267.00 (+0.79%)
  • Nasdaq Futures

    +81.75 (+0.52%)
  • Russell 2000 Futures

    +25.00 (+1.16%)
  • Crude Oil

    +0.93 (+1.42%)
  • Gold

    -4.90 (-0.27%)
  • Silver

    +0.10 (+0.43%)

    +0.0004 (+0.03%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    +3.93 (+14.45%)

    +0.0014 (+0.11%)

    +0.4020 (+0.36%)

    -297.36 (-0.52%)
  • CMC Crypto 200

    -28.35 (-1.93%)
  • FTSE 100

    +109.23 (+1.55%)
  • Nikkei 225

    -182.25 (-0.65%)

Some Analysts Just Cut Their Outlook Therapeutics, Inc. (NASDAQ:OTLK) Estimates

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Today is shaping up negative for Outlook Therapeutics, Inc. (NASDAQ:OTLK) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic. Shares are up 4.0% to US$0.75 in the past week. We'd be curious to see if the downgrade is enough to reverse investor sentiment on the business.

Following the latest downgrade, the current consensus, from the five analysts covering Outlook Therapeutics, is for revenues of US$260k in 2020, which would reflect a substantial 96% reduction in Outlook Therapeutics' sales over the past 12 months. Losses are predicted to fall substantially, shrinking 50% to US$0.78. Yet before this consensus update, the analysts had been forecasting revenues of US$488k and losses of US$0.76 per share in 2020. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

See our latest analysis for Outlook Therapeutics

NasdaqCM:OTLK Past and Future Earnings May 20th 2020
NasdaqCM:OTLK Past and Future Earnings May 20th 2020

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast revenue decline of 96%, a significant reduction from annual growth of 34% over the last three years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 24% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Outlook Therapeutics is expected to lag the wider industry.

The Bottom Line

The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Outlook Therapeutics. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. Given the stark change in sentiment, we'd understand if investors became more cautious on Outlook Therapeutics after today.

As you can see, the analysts clearly aren't bullish, and there might be good reason for that. We've identified some potential issues with Outlook Therapeutics' financials, such as a short cash runway. Learn more, and discover the 2 other warning signs we've identified, for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.